Interleukin-4 inhibition of osteoclast differentiation is stronger than that of interleukin-13 and they are equivalent for induction of osteoprotegerin production from osteoblasts

Immunology

Volumn 120, Issue 4, 2007, Pages 573-579

  Yamada, Atsushi ^a   Takami, Masamichi ^a   Kawawa, Tadaharu ^a   Yasuhara, Rika ^a   Zhao, Baohong ^a   Mochizuki, Ayako ^a   Miyamoto, Yoichi ^a   Eto, Tomoo ^b   Yasuda, Hisataka ^c   Nakamichi, Yuko ^d   Kim, Nacksung ^e   Katagiri, Takenobu ^f   Suda, Tatsuo ^f   Kamijo, Ryutaro ^a  

^a SHOWA UNIVERSITY   (Japan)

^b CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

^c Oriental Yeast Co Ltd   (Japan)

^d MATSUMOTO DENTAL UNIVERSITY   (Japan)

^e Chonnam National University Medical School   (South Korea)

^f SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Cellular differentiation; IL 13; IL 4; Osteoblasts; Osteoclasts

Indexed keywords

INTERLEUKIN 13; INTERLEUKIN 4; NUCLEAR FACTOR; STAT6 PROTEIN;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CYTOKINE PRODUCTION; DOSE RESPONSE; MALE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; BONE MARROW CELLS; CELL DIFFERENTIATION; COCULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; INTERLEUKIN-13; INTERLEUKIN-4; MACROPHAGES; MALE; MICE; NFATC TRANSCRIPTION FACTORS; OSTEOBLASTS; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STAT6 TRANSCRIPTION FACTOR;

EID: 33847622419     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2006.02538.x     Document Type: Article

References (30)

1. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999; 20:345-57.
2. Simonet WS, Lacey DL, Dunstan CR et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309-19.
3. Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T, Higashio K. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 1997; 234:137-42.
4. Yasuda H, Shima N, Nakagawa N et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998; 139:1329-37.
5. Bucay N, Sarosi I, Dunstan CR et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12:1260-8.
6. Mizuno A, Amizuka N, Irie K et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998; 247:610-5.
7. Takahashi N, Akatsu T, Udagawa N, Sasaki T, Yamaguchi A, Moseley JM, Martin TJ, Suda T. Osteoblastic cells are involved in osteoclast formation. Endocrinology 1988; 123:2600-2.
8. Yasuda H, Shima N, Nakagawa N et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95:3597-602.
9. Takami M, Kim N, Rho J, Choi Y. Stimulation by toll-like receptors inhibits osteoclast differentiation. J Immunol 2002; 169:1516-23.
10. Mundy GR. Role of cytokines in bone resorption. J Cell Biochem 1993; 53:296-300.
11. Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu Rev Immunol 1999; 17:255-81.
12. Callard RE, Matthews DJ, Hibbert L. IL-4 and IL-13 receptors: are they one and the same? Immunol Today 1996; 17:108-10.
13. Moreno JL, Kaczmarek M, Keegan AD, Tondravi M. IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: irreversible inhibition of the differentiation program activated by RANKL. Blood 2003; 102:1078-86.
14. Palmqvist P, Lundberg P, Persson E, Johansson A, Lundgren I, Lie A, Conaway HH, Lerner UH. Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway. J Biol Chem 2006; 281:2414-29.
15. Wong BR, Besser D, Kim N, Arron JR, Vologodskaia M, Hanafusa H, Choi Y. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol Cell 1999; 4:1041-9.
16. Wong BR, Rho J, Arron J et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997; 272:25190-4.
17. 3 in osteoclast differentiation and function. Methods Enzymol 1997; 282:223-35.
18. Yamada A, Sheikh F, Niimi T, DeMayo FJ, Keegan AD, Donnelly RP, Kimura S. Induction of uteroglobin-related protein 2 (Ugrp2) gene expression by the Th2 cytokines IL-4 and IL-13. J Immunol 2005; 175:5708-15.
19. Takayanagi H, Kim S, Koga T et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002; 3:889-901.
20. Watanabe K, Tanaka Y, Morimoto I, Yahata K, Zeki K, Fujihira T, Yamashita U, Eto S. Interleukin-4 as a potent inhibitor of bone resorption. Biochem Biophys Res Commun 1990; 172:1035-41.
21. Nakano Y, Watanabe K, Morimoto I et al. Interleukin-4 inhibits spontaneous and parathyroid hormone-related protein-stimulated osteoclast formation in mice. J Bone Miner Res 1994; 9:1533-9.
22. Okada Y, Morimoto I, Ura K, Nakano Y, Tanaka Y, Nishida S, Nakamura T, Eto S. Short-term treatment of recombinant murine interleukin-4 rapidly inhibits bone formation in normal and ovariectomized mice. Bone 1998; 22:361-5.
23. Ahlen J, Andersson S, Mukohyama H, Roth C, Backman A, Conaway HH, Lerner UH. Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones. Bone 2002; 31:242-51.
24. Nagasaki K, Yamaguchi K, Watanabe K, Eto S, Abe K. Interleukin-4 blocks parathyroid hormone-related protein-induced hypercalcemia in vivo. Biochem Biophys Res Commun 1991; 178:694-8.
25. Zurawski G, de Vries JE. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 1994; 15:19-26.
26. Chomarat P, Banchereau J. Interleukin-4 and interleukin-13: their similarities and discrepancies. Int Rev Immunol 1998; 17:1-52.
27. Welhm MJ, Learmonth L, Bone H, Schrader JW. Interleukin-13 signal transduction in lymphohemopoietic cells. J Biol Chem 1995; 270:2012286-96.
28. Miyamoto T, Ohneda O, Arai F, Iwamoto K, Okada S, Takagi K, Anderson DM, Suda T. Bifurcation of osteoclasts and dendritic cells from common progenitors. Blood 2001; 98:2544-54.
29. Wagner EF, Eferl R. Fos/AP-1 proteins in bone and the immune system. Immunol Rev 2005; 208:126-40.
30. Ahn JS, Agrawal B. IL-4 is more effective than IL-13 for in vitro differentiation of dendritic cells from peripheral blood mononuclear cells. Int Immunol 2005; 17:1337-46.